ViroLogic to Present at the UBS Global Life Sciences Conference on September 30, 2004
September 23 2004 - 6:08PM
PR Newswire (US)
ViroLogic to Present at the UBS Global Life Sciences Conference on
September 30, 2004 SOUTH SAN FRANCISCO, Calif., Sept. 23
/PRNewswire-FirstCall/ -- ViroLogic, Inc. (NASDAQ:VLGC) announced
today that Bill Young, CEO and Chairman, is scheduled to present a
corporate overview at the UBS Global Life Sciences Conference on
Thursday, September 30, 2004 at 11:00 a.m. This event will be held
at the Grand Hyatt Hotel in New York City. To access the live audio
broadcast or the subsequent archived recording log on to
http://www.virologic.com/ and go to the investor relations section.
The archived version of the webcast will be available online for
one month. About ViroLogic ViroLogic is a biotechnology company
advancing individualized medicine by discovering, developing and
marketing innovative products to guide and improve treatment of
serious viral diseases such as AIDS and hepatitis. The Company's
products are designed to help doctors optimize treatment regimens
that lead to better patient outcomes and reduced costs. ViroLogic's
technology is also being used by numerous biopharmaceutical
companies to develop new and improved anti-viral therapeutics and
vaccines targeted at emerging drug-resistant viruses. More
information about the Company and its technology can be found on
its website at http://www.virologic.com/. Certain statements in
this press release are forward-looking. These forward-looking
statements are subject to risks and uncertainties and other
factors, which may cause actual results to differ materially from
the anticipated results or other expectations expressed in such
forward-looking statements. These risks and uncertainties include,
but are not limited to, the timing of pharmaceutical company
clinical trials, risks related to our pending merger with ACLARA
BioSciences, Inc. (ACLARA), including the risk that the closing
conditions of the merger may not be satisfied and the merger may
not be completed, and costs related to the proposed merger may
adversely impact ViroLogic's financial performance, the risks that
the Company's products may not perform, whether ViroLogic
successfully introduces new products, risks related to the
implementation of the Company's distribution agreement with a major
national laboratory, whether others introduce competitive products,
the risk that the Company's products for patient testing may not
continue to be accepted or that increased demand from drug
development partners may not develop as anticipated, the risk that
gross margins may not increase as expected, whether payors will
authorize reimbursement for its products, whether the FDA or any
other agency will decide to regulate ViroLogic's products or
services, whether the Company will encounter problems or delays in
automating its processes, whether intellectual property underlying
the Company's PhenoSense(TM) technology is adequate, whether
licenses to third party technology will be available, whether
ViroLogic is able to build brand loyalty and expand revenues, and
whether ViroLogic will be able to raise sufficient capital when
required. For a discussion of other factors that may cause
ViroLogic's actual events to differ from those projected, please
refer to the Company's most recent annual report on Form 10-K,
quarterly reports on Form 10-Q, and the preliminary Joint
Proxy/Prospectus related to the proposed merger with ACLARA, as
well as other subsequent filings with the Securities and Exchange
Commission. DATASOURCE: ViroLogic, Inc. CONTACT: Karen Wilson, CFO
of ViroLogic, Inc., +1-650-624-4164, or Web site:
http://www.virologic.com/
Copyright
Virologic (NASDAQ:VLGC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Virologic (NASDAQ:VLGC)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Virologic (MM) (NASDAQ): 0 recent articles
More Virologic (MM) News Articles